Suppr超能文献

2015 至 2019 年,亚美尼亚 HIV 相关结核病患者不良治疗结局的相关因素。

Factors associated with unfavourable treatment outcomes in people with HIV-associated tuberculosis in Armenia, 2015 to 2019.

机构信息

Yerevan State Medical University after Mkhitar Heratsi, Yerevan.

Tuberculosis Research and Prevention Center, Yerevan.

出版信息

Monaldi Arch Chest Dis. 2021 Jan 14;91(1). doi: 10.4081/monaldi.2021.1648.

Abstract

To evaluate factors associated with tuberculosis (TB) treatment outcomes in human Immunodeficiency Virus-Associated (HIV) TB patients in Armenia, we conducted a nation-wide cohort study using routine programmatic data of all HIV-associated TB patients receiving TB treatment with first- or second-line drugs from 2015 to 2019. Data were obtained from the TB and HIV electronic databases. We analysed occurrence of the combined unfavourable outcome (failure, lost to follow-up, death and not evaluated) and death separately, and factors associated with both outcomes using Cox regression. There were 320 HIV-associated TB patients who contributed a total of 351 episodes of TB treatment. An unfavourable TB treatment outcome was registered in 155 (44.2%) episodes, including 85 (24.2%) due to death, 38 (10.8%) lost to follow up, 13 (3.7%) failure and 19 (5.4%) not evaluated. Multivariable analysis showed that receipt of Antiretroviral Treatment (ART) [ART start before TB treatment: adjusted hazard ratio (aHR)=0.3, 95% confidence interval (CI): 0.2-0.5, aHR=, 95% CI:, 95% CI:, 95% CI:TB meningitis (aHR=4.4, 95% CI: 1.6-11.9) increased the risk. The risk of death was affected by the same factors as above in addition to the low BMI (aHR=2.5, 95% CI: 1.3-4.5) and drug resistance (aHR=2.3, 95% CI: 1.0-5.4). In the subsample of episodes receiving ART, history of interruption of ART during TB treatment increased the risk of unfavourable outcome (aHR=2.1 95% CI: 1.2-3.9), while ART start during TB treatment was associated with lower risk of both unfavourable outcome (within first 8 weeks: aHR: 0.5, 95% CI: 0.3-0.9; after 8 weeks: aHR: 0.4, 95% CI: 0.2-1.0) and death (within first 8 weeks: aHR: 0.2, 95% CI: 0.1-0.4; after 8 weeks: aHR: 0.1, 95% CI: 0.01-0.3). The rates of unfavourable TB treatment outcomes, and death in particular, among HIV-associated TB patients in Armenia are high. Our findings emphasize the protective effect of ART and the importance of proper management of cases complicated by drug resistance or meningitis.

摘要

为了评估与亚美尼亚人类免疫缺陷病毒相关性结核病(HIV-TB)患者的结核病(TB)治疗结局相关的因素,我们利用 2015 年至 2019 年所有接受一线或二线药物治疗的 HIV 相关性 TB 患者的常规规划数据,进行了一项全国性队列研究。数据来自 TB 和 HIV 电子数据库。我们分别分析了联合不良结局(失败、失访、死亡和未评估)和死亡的发生情况,并使用 Cox 回归分析了这两种结局的相关因素。共有 320 名 HIV 相关性 TB 患者,共贡献了 351 例 TB 治疗期。155 例(44.2%)出现不良 TB 治疗结局,其中 85 例(24.2%)因死亡,38 例(10.8%)失访,13 例(3.7%)治疗失败,19 例(5.4%)未评估。多变量分析表明,接受抗逆转录病毒治疗(ART)[在结核病治疗前开始 ART:调整后的危险比(aHR)=0.3,95%置信区间(CI):0.2-0.5,aHR=0.3,95%CI:0.1-0.6,aHR=0.1,95%CI:0.01-0.4]和结核病脑膜炎(aHR=4.4,95%CI:1.6-11.9)增加了风险。死亡风险还受到上述所有因素的影响,此外还受到低 BMI(aHR=2.5,95%CI:1.3-4.5)和耐药性(aHR=2.3,95%CI:1.0-5.4)的影响。在接受 ART 的治疗期病例亚组中,结核病治疗期间中断 ART 的历史增加了不良结局的风险(aHR=2.1,95%CI:1.2-3.9),而结核病治疗期间开始 ART 与不良结局(第 8 周内:aHR:0.5,95%CI:0.3-0.9;第 8 周后:aHR:0.4,95%CI:0.2-1.0)和死亡(第 8 周内:aHR:0.2,95%CI:0.1-0.4;第 8 周后:aHR:0.1,95%CI:0.01-0.3)的风险降低相关。亚美尼亚 HIV 相关性 TB 患者的不良 TB 治疗结局发生率,特别是死亡率很高。我们的研究结果强调了 ART 的保护作用,以及妥善管理耐药或脑膜炎合并症病例的重要性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验